Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1962 1
1963 1
1964 2
1965 1
1980 1
1981 8
1982 11
1983 11
1984 1
1985 4
1986 3
1987 8
1989 3
1990 3
1991 2
1993 2
1994 2
1995 10
1996 3
1997 7
1998 11
1999 10
2000 10
2001 11
2002 7
2003 11
2004 6
2005 11
2006 7
2007 11
2008 11
2009 16
2010 11
2011 9
2012 7
2013 16
2014 13
2015 15
2016 21
2017 26
2018 31
2019 30
2020 32
2021 60
2022 56
2023 5
Text availability
Article attribute
Article type
Publication date

Search Results

484 results
Results by year
Filters applied: . Clear all
Page 1
Structure of the miniature type V-F CRISPR-Cas effector enzyme.
Takeda SN, Nakagawa R, Okazaki S, Hirano H, Kobayashi K, Kusakizako T, Nishizawa T, Yamashita K, Nishimasu H, Nureki O. Takeda SN, et al. Among authors: nakagawa r. Mol Cell. 2021 Feb 4;81(3):558-570.e3. doi: 10.1016/j.molcel.2020.11.035. Epub 2020 Dec 16. Mol Cell. 2021. PMID: 33333018 Free article.
Amplification-free RNA detection with CRISPR-Cas13.
Shinoda H, Taguchi Y, Nakagawa R, Makino A, Okazaki S, Nakano M, Muramoto Y, Takahashi C, Takahashi I, Ando J, Noda T, Nureki O, Nishimasu H, Watanabe R. Shinoda H, et al. Among authors: nakagawa r. Commun Biol. 2021 Apr 19;4(1):476. doi: 10.1038/s42003-021-02001-8. Commun Biol. 2021. PMID: 33875803 Free PMC article.
Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.
Lee JV, Housley F, Yau C, Nakagawa R, Winkler J, Anttila JM, Munne PM, Savelius M, Houlahan KE, Van de Mark D, Hemmati G, Hernandez GA, Zhang Y, Samson S, Baas C, Kok M, Esserman LJ, van 't Veer LJ, Rugo HS, Curtis C, Klefström J, Matloubian M, Goga A. Lee JV, et al. Among authors: nakagawa r. Nat Commun. 2022 Jun 27;13(1):3671. doi: 10.1038/s41467-022-31238-y. Nat Commun. 2022. PMID: 35760778 Free PMC article.
A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial.
Guimarães HP, de Barros E Silva PGM, Liporace IL, Sampaio RO, Tarasoutchi F, Paixão M, Hoffmann-Filho CR, Patriota R, Leiria TLL, Lamprea D, Precoma DB, Atik FA, Silveira FS, Farias FR, Barreto DO, Almeida AP, Zilli AC, de Souza Neto JD, Cavalcante MA, Figueira FAMS, Junior RA, Moisés VA, Mesas CE, Ardito RV, Kalil PSA, Paiva MSMO, Maldonado JGA, de Lima CEB, D'Oliveira Vieira R, Laranjeira L, Kojima F, Damiani L, Nakagawa RH, Dos Santos JRY, Sampaio BS, Campos VB, Saraiva JFK, Fonseca FH, Pinto IM, Magalhães CC, Ferreira JFM, Lopes RD, Pavanello R, Cavalcanti AB, Berwanger O; RIVER (RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER Trial) Investigators. Guimarães HP, et al. Among authors: nakagawa rh. Am Heart J. 2021 Jan;231:128-136. doi: 10.1016/j.ahj.2020.10.001. Epub 2020 Oct 10. Am Heart J. 2021. PMID: 33045224 Clinical Trial.
Chemoproteomic Identification of Blue-Light-Damaged Proteins.
Toh K, Nishio K, Nakagawa R, Egoshi S, Abo M, Perron A, Sato SI, Okumura N, Koizumi N, Dodo K, Sodeoka M, Uesugi M. Toh K, et al. Among authors: nakagawa r. J Am Chem Soc. 2022 Nov 9;144(44):20171-20176. doi: 10.1021/jacs.2c07180. Epub 2022 Oct 28. J Am Chem Soc. 2022. PMID: 36306265
Treatment Outcomes in Neuroendocrine Prostate Cancer.
Iwamoto H, Nakagawa R, Makino T, Kadomoto S, Yaegashi H, Nohara T, Shigehara K, Izumi K, Kadono Y, Mizokami A. Iwamoto H, et al. Among authors: nakagawa r. Anticancer Res. 2022 Apr;42(4):2167-2176. doi: 10.21873/anticanres.15699. Anticancer Res. 2022. PMID: 35347041
Structure and engineering of the minimal type VI CRISPR-Cas13bt3.
Nakagawa R, Kannan S, Altae-Tran H, Takeda SN, Tomita A, Hirano H, Kusakizako T, Nishizawa T, Yamashita K, Zhang F, Nishimasu H, Nureki O. Nakagawa R, et al. Mol Cell. 2022 Sep 1;82(17):3178-3192.e5. doi: 10.1016/j.molcel.2022.08.001. Epub 2022 Aug 25. Mol Cell. 2022. PMID: 36027912 Free PMC article.
Changes in therapeutic options for hepatocellular carcinoma in Asia.
Ogasawara S, Koroki K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Kato N. Ogasawara S, et al. Among authors: nakagawa r. Liver Int. 2022 Aug;42(9):2055-2066. doi: 10.1111/liv.15101. Epub 2021 Nov 29. Liver Int. 2022. PMID: 34780081 Review.
Structure of the type V-C CRISPR-Cas effector enzyme.
Kurihara N, Nakagawa R, Hirano H, Okazaki S, Tomita A, Kobayashi K, Kusakizako T, Nishizawa T, Yamashita K, Scott DA, Nishimasu H, Nureki O. Kurihara N, et al. Among authors: nakagawa r. Mol Cell. 2022 May 19;82(10):1865-1877.e4. doi: 10.1016/j.molcel.2022.03.006. Epub 2022 Apr 1. Mol Cell. 2022. PMID: 35366394 Free PMC article.
484 results